LXRX Lexicon Pharmaceuticals, Inc.

15.00
+0  (0%)
Previous Close 14.93
Open 15.00
Price To book 9.89
Market Cap 1.56B
Shares 104,319,000
Volume 459,963
Short Ratio 12.34
Av. Daily Volume 908,623

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial did not meet primary endpoint.
Sotagliflozin
Type 1 Diabetes
Phase 3 data released September 9, 2016 met primary endpoint. Data from second trial released December 21, 2016 - primary endpoint met. Data from third trial due mid-2017.
Sotagliflozin
Type 1 Diabetes
Approved February 28, 2017.
Telotristat etiprate (XERMELO)
Carcinoid Syndrome
Phase 3 trial initiated 4Q 2016.
Sotagliflozin
Type 2 Diabetes

Latest News

  1. Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LXRX-US : April 14, 2017
  2. 3 Top Biotech Stocks to Buy in April
  3. Lexicon To Present At The 16th Annual Needham Healthcare Conference
  4. What Does Big Pharma Want To Buy? 3 Drugmakers On Merger Track
  5. 3 Tremendously Promising Diabetes Drugs Potentially on the Way
  6. Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LXRX-US : March 20, 2017
  7. Surging Earnings Estimates Signal Good News for Lexicon (LXRX)
  8. Lexicon To Present At The Barclays Global Healthcare Conference
  9. Lexicon Pharmaceuticals, Inc. :LXRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017
  10. Lexicon To Present At The Cowen And Company 37th Annual Healthcare Conference
  11. Edited Transcript of LXRX earnings conference call or presentation 3-Mar-17 3:00pm GMT
  12. Wedbush Has 3 Biotech Stocks to Buy With Massive Upside Potential
  13. Biotech Premarket Movers: Karyopharm, Lexicon, Prothena
  14. Lexicon reports 4Q loss
  15. Biotech's Outlook Strengthens After President Trump's Speech: Today's Reports on Dynavax Technologies and Lexicon Pharmaceuticals
  16. Lexicon To Report Fourth Quarter And Year End 2016 Financial Results On March 3, 2017
  17. Here’s What’s Next For Lexicon Pharmaceuticals, Inc. (LXRX) And Dynavax Technologies Corporation (DVAX)
  18. Lexicon Stock Spikes 8% on Diarrhea Drug Approval
  19. UPDATE 1-FDA approves Lexicon Pharma's carcinoid syndrome diarrhea drug